Hepatology
Conference Coverage
Weight-loss drugs improve liver measures, too
Body weight reduction of at least 3% within 8 weeks of beginning treatment with either an SLT-2 or GLP-1 agent was associated independently with...
Latest News
MASLD, MASH projected to grow by 23% in the U.S. through 2050
“In the absence of effective treatments, health systems should plan for large increases in the number of liver cancer cases and the need for liver...
News
Test all perinatally exposed infants for HCV: CDC
The CDC noted that rates of HCV infections during pregnancy are on the rise.
Latest News
Tech encourages HIV prevention among women
“Mobile technologies, in particular, offer a nimble, customizable, and accessible way to reach this target population and increase awareness of...
Latest News
MASLD linked to increased risk for various clinical outcomes
The disease significantly raises the risk for cardiovascular, metabolic, oncologic, and other outcomes.
Latest News
Early-onset NAFLD tied to higher cancer risk
Among adults younger than 45 at NAFLD onset, cancers were mainly digestive and lung cancers.
Latest News
No need to restrict hep C DAA therapy based on alcohol use
Alcohol use is not associated with decreased odds of a sustained virologic response to direct-acting antiviral therapy.
Latest News
Primary care clinicians should spearhead HIV prevention
U.S. Preventive Services Task Force guidelines call for clinicians to prescribe pre-exposure prophylaxis drugs to adolescents and adults who do...
Latest News
NAFLD raises risk for colorectal adenomatous polyps
In the fully adjusted model, NAFLD was a significant independent risk factor for adenomatous polyps but not for nonadenomatous polyps.
Latest News
New consensus on managing acetaminophen poisoning
The panel emphasized the role of the patient’s history; an inaccurate estimate of the time of ingestion can lead to the erroneous conclusion that...
Latest News
A decade after first DAA, only one in three are HCV free
Patients face barriers to being cured at every step of the way, from being diagnosed to accessing breakthrough DAA agents.